View ValuationCorbion 향후 성장Future 기준 점검 1/6Corbion (는) 각각 연간 12.2% 및 2.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 11.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 12.7% 로 예상됩니다.핵심 정보12.2%이익 성장률11.53%EPS 성장률Chemicals 이익 성장20.9%매출 성장률2.5%향후 자기자본이익률12.67%애널리스트 커버리지Good마지막 업데이트08 May 2026최근 향후 성장 업데이트공시 • Apr 24Corbion N.V. Affirms Earnings Guidance for Fiscal Year 2026Corbion N.V. affirmed earnings guidance for Fiscal Year 2026. For the period, the company expects to deliver guidance on all forecasted metrics, including sales growth.Price Target Changed • Jan 17Price target increased by 8.3% to €24.37Up from €22.50, the current price target is an average from 7 analysts. New target price is 25% above last closing price of €19.42. Stock is down 16% over the past year. The company is forecast to post earnings per share of €1.30 for next year compared to €0.79 last year.Price Target Changed • Apr 23Price target decreased by 7.0% to €24.33Down from €26.17, the current price target is an average from 6 analysts. New target price is 34% above last closing price of €18.22. Stock is down 3.6% over the past year. The company is forecast to post earnings per share of €1.36 for next year compared to €0.79 last year.Major Estimate Revision • Feb 06Consensus EPS estimates increase by 18%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate increased from €1.00 to €1.18. Revenue forecast steady at €1.44b. Net income forecast to grow 3.3% next year vs 12% growth forecast for Chemicals industry in the Netherlands. Consensus price target of €22.75 unchanged from last update. Share price fell 3.1% to €18.33 over the past week.Price Target Changed • Feb 06Price target decreased by 9.5% to €22.10Down from €24.42, the current price target is an average from 6 analysts. New target price is 21% above last closing price of €18.33. Stock is down 49% over the past year. The company is forecast to post earnings per share of €1.15 for next year compared to €1.53 last year.Price Target Changed • Oct 25Price target decreased by 9.7% to €26.33Down from €29.17, the current price target is an average from 6 analysts. New target price is 65% above last closing price of €15.94. Stock is down 41% over the past year. The company is forecast to post earnings per share of €0.99 for next year compared to €1.53 last year.모든 업데이트 보기Recent updates공시 • May 15Corbion N.V. Approves Special Dividend for the Financial Year 2025, Payable on 22 May 2026Corbion N.V. at the Annual General Shareholders Meeting held on 13 May 2026 approved dividend of €1.00 per share comprising a special dividend of €0.36 per share for the financial year 2025. Dividend will be all-cash and will in principle be subject to Dutch dividend withholding tax of 15%. The ex-dividend date is 15 May 2026, the record date is 18 May 2026, and the payment date is 22 May 2026.공시 • May 14+ 1 more updateCorbion N.V. Approves Regular Dividend for the Financial Year 2025, Payable on 22 May 2026Corbion N.V. at the Annual General Shareholders Meeting held on 13 May 2026 approved dividend of €1.00 per share comprising a regular dividend of €0.64 per share for the financial year 2025. Dividend will be all-cash and will in principle be subject to Dutch dividend withholding tax of 15%. The ex-dividend date is 15 May 2026, the record date is 18 May 2026, and the payment date is 22 May 2026.내러티브 업데이트 • May 09CRBN: Special Dividend And Higher Future P E Could Support Re RatingAnalysts have reduced their fair value estimate for Corbion from €30.00 to €28.00, citing updated assumptions for revenue growth, profit margins and future P/E following recent research, including the Barclays downgrade. Analyst Commentary Recent research has led to a lower fair value estimate for Corbion, but bullish analysts still highlight several supports for the stock, focusing on how current assumptions around revenue, margins and P/E could play out over time.Upcoming Dividend • May 08Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 15 May 2026. Payment date: 22 May 2026. Payout ratio is a comfortable 50% and this is well supported by cash flows. Trailing yield: 3.4%. Lower than top quartile of Dutch dividend payers (5.0%). Lower than average of industry peers (8.8%).공시 • Apr 24Corbion N.V. Affirms Earnings Guidance for Fiscal Year 2026Corbion N.V. affirmed earnings guidance for Fiscal Year 2026. For the period, the company expects to deliver guidance on all forecasted metrics, including sales growth.내러티브 업데이트 • Apr 22CRBN: Special Dividend And Execution On Margins Will Support Upside PotentialThe updated analyst price target for Corbion has shifted slightly to about €24.03 from €24.17, as analysts adjust their assumptions around discount rate, revenue growth, profit margin and future P/E in light of recent research, including the Barclays downgrade. Analyst Commentary Bullish Takeaways Bullish analysts see the updated price target around €24.03 as still leaving some room for upside if Corbion executes well on its revenue and margin assumptions embedded in the models.내러티브 업데이트 • Apr 08CRBN: Raised Fair Value And Barclays Downgrade Will Shape Risk BalanceAnalysts now set Corbion's fair value at €19.60, up from €18.60. This reflects updated assumptions on growth, margins and P/E multiples, even as some recent research, including a downgrade at Barclays, highlights ongoing risks.Declared Dividend • Apr 04Dividend of €1.00 announcedShareholders will receive a dividend of €1.00. Ex-date: 15th May 2026 Payment date: 22nd May 2026 Dividend yield will be 5.3%, which is higher than the industry average of 3.2%. Sustainability & Growth Dividend is well covered by both earnings (50% earnings payout ratio) and cash flows (40% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 33% over the next 3 years, which should provide support to the dividend and adequate earnings cover.내러티브 업데이트 • Mar 24CRBN: Higher Margins And Special Dividend Will Support Future Re RatingAnalysts have maintained their price target for Corbion at €30.00, citing updated assumptions around the discount rate, revenue growth, profit margin and future P/E as the main factors supporting the unchanged view. What's in the News Corbion N.V. proposed a special dividend of €0.36 per share, planned for distribution in 2025.내러티브 업데이트 • Mar 10CRBN: Special Dividend And Stronger Margins Will Support A More Optimistic OutlookAnalysts have trimmed their price target on Corbion from €24.60 to about €24.17, reflecting updated views on its projected revenue growth, profit margins, and future P/E assumptions. What's in the News Corbion N.V. proposed a special dividend of €0.36 per share for 2025, which may influence your expected cash returns from holding the stock (Key Developments).Reported Earnings • Mar 02Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: €1.29 (up from €0.79 in FY 2024). Revenue: €1.27b (down 1.6% from FY 2024). Net income: €74.8m (up 63% from FY 2024). Profit margin: 5.9% (up from 3.6% in FY 2024). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.1%. Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.공시 • Feb 27Corbion N.V., Annual General Meeting, May 13, 2026Corbion N.V., Annual General Meeting, May 13, 2026.공시 • Feb 26+ 1 more updateCorbion N.V. Proposes Dividend for the Year 2025Corbion N.V. proposed to distribute regular dividend of €0.64 per share for 2025.내러티브 업데이트 • Feb 24CRBN: Higher Future P/E Assumptions Will Support A More Optimistic OutlookAnalysts have raised their price target on Corbion from about €22.73 to €24.60, citing updated assumptions on discount rates, revenue growth, profit margins, and future P/E levels. Valuation Changes Fair Value: Updated estimate increased from about €22.73 to €24.60 per share.내러티브 업데이트 • Feb 09CRBN: Buyback And Higher Discount Rate Will Pressure Overvalued SharesAnalysts have kept their price target on Corbion steady at €18.60, citing only small adjustments to assumptions around the discount rate, revenue trends, profit margins and future P/E as the basis for this unchanged view. What's in the News Corbion completed a share buyback program, repurchasing 577,615 shares for €10 million, equal to 0.99% of the company.내러티브 업데이트 • Jan 26CRBN: Higher Future P/E And Execution Risks Will Shape EUR 18 OutlookNarrative Update on Corbion Analysts have raised their fair value estimate for Corbion to €18.60 from €18.00. This reflects updated views on discount rates, long term revenue trends, profit margins, and a higher future P/E assumption, alongside recent Street research where a key price target moved to €18 from €16.50.Price Target Changed • Jan 17Price target increased by 8.3% to €24.37Up from €22.50, the current price target is an average from 7 analysts. New target price is 25% above last closing price of €19.42. Stock is down 16% over the past year. The company is forecast to post earnings per share of €1.30 for next year compared to €0.79 last year.분석 기사 • Jan 14Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?Corbion N.V. ( AMS:CRBN ), is not the largest company out there, but it saw a double-digit share price rise of over 10...내러티브 업데이트 • Jan 11CRBN: Future P/E Reset And Margin Assumptions Will Shape EUR 18 OutlookAnalysts have raised their price target for Corbion to €18 from €16.50, citing updated assumptions on revenue trends, margins and future P/E as the main factors behind the change. Analyst Commentary The revised €18 price target still comes with a Hold stance, which signals a measured view on Corbion.내러티브 업데이트 • Dec 26CRBN: Higher EUR 18 Outlook Will Test Margin Delivery Amid Muted DemandAnalysts have raised their fair value estimate for Corbion to EUR 18 from EUR 14, reflecting increased confidence in the company’s profit margin outlook and a willingness to apply a higher future earnings multiple despite more muted revenue growth expectations. Analyst Commentary Bearish analysts acknowledge the higher fair value estimate but continue to highlight a cautious stance on Corbion’s near term prospects, emphasizing that the improved target largely reflects valuation mechanics rather than a fundamental re-rating of the growth outlook.내러티브 업데이트 • Dec 12CRBN: Margin Improvements And Buybacks Will Support A Future Re-RatingAnalysts have lowered their fair value price target on Corbion to EUR 30.00 from EUR 31.90, citing tempered expectations for long term revenue growth and profit margins, even as some recent Street research has modestly raised nearer term share price targets. Analyst Commentary Bullish analysts highlight that the recent upward revision in near term price targets, even from a relatively low base, reflects growing confidence that Corbion can stabilize its earnings profile and execute on margin improvement initiatives.분석 기사 • Nov 14Corbion N.V. (AMS:CRBN) Shares Could Be 35% Below Their Intrinsic Value EstimateKey Insights Using the 2 Stage Free Cash Flow to Equity, Corbion fair value estimate is €28.50 Current share price of...공시 • Oct 09+ 2 more updatesCorbion N.V. to Report Fiscal Year 2025 Results on Feb 26, 2026Corbion N.V. announced that they will report fiscal year 2025 results on Feb 26, 2026Reported Earnings • Aug 05First half 2025 earnings released: EPS: €0.73 (vs €0.39 in 1H 2024)First half 2025 results: EPS: €0.73 (up from €0.39 in 1H 2024). Revenue: €645.6m (up 1.3% from 1H 2024). Net income: €42.4m (up 87% from 1H 2024). Profit margin: 6.6% (up from 3.6% in 1H 2024). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.분석 기사 • Jun 23Corbion N.V.'s (AMS:CRBN) Intrinsic Value Is Potentially 65% Above Its Share PriceKey Insights The projected fair value for Corbion is €30.72 based on 2 Stage Free Cash Flow to Equity Current share...Upcoming Dividend • May 09Upcoming dividend of €0.64 per shareEligible shareholders must have bought the stock before 16 May 2025. Payment date: 27 May 2025. Payout ratio is on the higher end at 81%, however this is supported by cash flows. Trailing yield: 3.3%. Lower than top quartile of Dutch dividend payers (5.6%). Higher than average of industry peers (2.9%).분석 기사 • May 07Here's Why Shareholders Should Examine Corbion N.V.'s (AMS:CRBN) CEO Compensation Package More CloselyKey Insights Corbion's Annual General Meeting to take place on 14th of May Salary of €725.0k is part of CEO Olivier...Price Target Changed • Apr 23Price target decreased by 7.0% to €24.33Down from €26.17, the current price target is an average from 6 analysts. New target price is 34% above last closing price of €18.22. Stock is down 3.6% over the past year. The company is forecast to post earnings per share of €1.36 for next year compared to €0.79 last year.분석 기사 • Apr 10At €17.39, Is Corbion N.V. (AMS:CRBN) Worth Looking At Closely?Corbion N.V. ( AMS:CRBN ), might not be a large cap stock, but it saw significant share price movement during recent...Declared Dividend • Apr 04Final dividend of €0.64 announcedShareholders will receive a dividend of €0.64. Ex-date: 16th May 2025 Payment date: 27th May 2025 Dividend yield will be 3.4%, which is higher than the industry average of 3.2%. Sustainability & Growth Dividend is covered by both earnings (81% earnings payout ratio) and cash flows (37% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 108% over the next 3 years, which should provide support to the dividend and adequate earnings cover.공시 • Apr 03Corbion N.V. announces Annual dividend, payable on May 27, 2025Corbion N.V. announced Annual dividend of EUR 0.6400 per share payable on May 27, 2025, ex-date on May 16, 2025 and record date on May 19, 2025.분석 기사 • Mar 26Corbion's (AMS:CRBN) Earnings May Just Be The Starting PointCorbion N.V.'s ( AMS:CRBN ) earnings announcement last week was disappointing for investors, despite the decent profit...새로운 내러티브 • Mar 02Expanding Into Natural Antioxidants And Efficiency Improvements Will Drive Future Success Strategic initiatives and operational optimizations are expected to significantly enhance EBITDA margins and net margins.Reported Earnings • Feb 28Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: EPS: €0.79 (down from €1.23 in FY 2023). Revenue: €1.29b (down 11% from FY 2023). Net income: €45.9m (down 37% from FY 2023). Profit margin: 3.6% (down from 5.0% in FY 2023). The decrease in margin was driven by lower revenue. Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates significantly. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings.분석 기사 • Feb 28Here's What To Make Of Corbion's (AMS:CRBN) Decelerating Rates Of ReturnWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...공시 • Feb 28Corbion N.V., Annual General Meeting, May 14, 2025Corbion N.V., Annual General Meeting, May 14, 2025.공시 • Feb 27Corbion N.V. Proposes Regular Cash DividendCorbion N.V. proposed a regular cash dividend increase of +5% to €0.64 per ordinary share to be submitted for approval to the annual General Meeting of Shareholders.Buy Or Sell Opportunity • Feb 14Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 4.4% to €22.80. The fair value is estimated to be €18.99, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has declined by 12%. For the next 3 years, revenue is forecast to grow by 1.5% per annum. Earnings are also forecast to grow by 10% per annum over the same time period.분석 기사 • Dec 18Risks To Shareholder Returns Are Elevated At These Prices For Corbion N.V. (AMS:CRBN)It's not a stretch to say that Corbion N.V.'s ( AMS:CRBN ) price-to-earnings (or "P/E") ratio of 15.8x right now seems...분석 기사 • Nov 18Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?Corbion N.V. ( AMS:CRBN ), might not be a large cap stock, but it received a lot of attention from a substantial price...분석 기사 • Oct 31An Intrinsic Calculation For Corbion N.V. (AMS:CRBN) Suggests It's 26% UndervaluedKey Insights Using the 2 Stage Free Cash Flow to Equity, Corbion fair value estimate is €31.60 Corbion's €23.28 share...Buy Or Sell Opportunity • Oct 30Now 21% undervaluedOver the last 90 days, the stock has risen 24% to €25.42. The fair value is estimated to be €32.03, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has declined by 12%. Revenue is forecast to decline by 5.2% in 2 years. Earnings are forecast to grow by 15% in the next 2 years.New Risk • Oct 30New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.5% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.5% per year for the foreseeable future. Minor Risks High level of debt (51% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.공시 • Oct 25+ 1 more updateCorbion N.V. to Report Q2, 2025 Results on Jul 31, 2025Corbion N.V. announced that they will report Q2, 2025 results on Jul 31, 2025분석 기사 • Sep 26Corbion (AMS:CRBN) Takes On Some Risk With Its Use Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Aug 12First half 2024 earnings released: EPS: €0.39 (vs €0.26 in 1H 2023)First half 2024 results: EPS: €0.39 (up from €0.26 in 1H 2023). Revenue: €637.1m (flat on 1H 2023). Net income: €22.7m (up 47% from 1H 2023). Profit margin: 3.6% (up from 2.4% in 1H 2023). Revenue is forecast to stay flat during the next 3 years compared to a 4.7% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.분석 기사 • Jul 18The Price Is Right For Corbion N.V. (AMS:CRBN)It's not a stretch to say that Corbion N.V.'s ( AMS:CRBN ) price-to-earnings (or "P/E") ratio of 16.1x right now seems...분석 기사 • Jun 20Corbion N.V. (AMS:CRBN) Shares Could Be 25% Below Their Intrinsic Value EstimateKey Insights Using the 2 Stage Free Cash Flow to Equity, Corbion fair value estimate is €25.18 Corbion is estimated to...Buy Or Sell Opportunity • May 31Now 20% undervaluedOver the last 90 days, the stock has risen 4.2% to €20.38. The fair value is estimated to be €25.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has declined by 9.7%. For the next 3 years, revenue is forecast to grow by 0.3% per annum. Earnings are also forecast to grow by 17% per annum over the same time period.분석 기사 • May 08Here's Why Shareholders Should Examine Corbion N.V.'s (AMS:CRBN) CEO Compensation Package More CloselyKey Insights Corbion will host its Annual General Meeting on 15th of May Salary of €713.0k is part of CEO Olivier...Declared Dividend • May 03Final dividend of €0.61 announcedShareholders will receive a dividend of €0.61. Ex-date: 17th May 2024 Payment date: 28th May 2024 Dividend yield will be 3.4%, which is higher than the industry average of 3.2%. Sustainability & Growth Dividend is covered by earnings (49% earnings payout ratio) but not covered by cash flows (224% cash payout ratio). The dividend has increased by an average of 15% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 54% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Buy Or Sell Opportunity • Apr 26Now 23% overvaluedOver the last 90 days, the stock has fallen 1.5% to €19.28. The fair value is estimated to be €15.63, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has declined by 9.7%. For the next 3 years, revenue is forecast to grow by 0.6% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.분석 기사 • Apr 17Does Corbion (AMS:CRBN) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...공시 • Apr 12Corbion Appoints Masha Vis-Mertens as Chief Human Resources Officer and Member of the Executive Committee as of 1 May 2024Corbion announced appointment of Masha Vis-Mertens as Chief Human Resources Officer and member of the Executive Committee as of 1 May 2024. Masha Vis-Mertens, a Dutch national, joins Corbion from Switzerland where she was most recently Chief Human Resources Officer of Barry Callebaut, a global Cocoa and Chocolate Manufacturer. Over her career, she has lived in various regions and countries and has been a successful leader in HR, Commercial and Supply Chain roles. In her previous positions she gained a wealth of experience in talent development, diversity and inclusion, culture, and organizational transformation that she will be bringing to Corbion. Masha brings a diverse and multi-cultural background and a fresh perspective. She worked internationally throughout her career and is fluent in Dutch, German, French and English.공시 • Apr 03Kingswood Capital Management, L.P. completed the acquisition of Emulsifiers business from Corbion N.V.Kingswood Capital Management, L.P. singed a binding agreement to acquire Emulsifiers business from Corbion N.V for $362 million on January 26, 2024. The purchase price paid for the business is $362 million with expected net cash proceeds of approximately $275 million, post tax and transaction costs. The sale, which is contingent upon the satisfaction of certain conditions, including regulatory approvals and transaction is expected to close in the second quarter of this year. Kirkland & Ellis LLP acted as legal advisor and Configure Partners, LLC acted as debt advisor to Kingswood Capital Management, L.P. Lazard B.V. acted as financial advisor and Stinson LLP acted as legal advisor to Corbion N.V. Kingswood Capital Management, L.P. completed the acquisition of Emulsifiers business from Corbion N.V on April 2, 2024. The emulsifiers business, moving forward, will operate under the name PATCO Products, LLC and Vice President of Emulsifiers at Corbion, John Miller, will continue to lead the Company as its Chief Executive Officer.공시 • Mar 05Corbion Announces Preliminary Results of New Study from Millennial Salmon ProjectCorbion announced preliminary results of a new study from the Millennial Salmon Project, a strategic partnership among organizations along the value chain of salmon production. Conducted by Nofima and recently published in Aquaculture, the study confirms that AlgaPrime™ DHA can be added at varying levels without negatively impacting feed quality, and actually promoting a more stable process and pellet quality. Primarily funded by the Research Council of Norway and made up of leading organizations Nofima, InnovaFeed, Corbion,Cargill, MOWI, Labeyrie Fine Foods, SINTEF Ocean and Auchan, the Millennial Salmon Project aims to create the world’s most sustainable farmed salmon using novel ingredients with a low carbon footprint and a focus on the circular economy. The first round of research sought to determine optimal inclusion levels of AlgaPrime™ DHA LS — Corbion’s algae-based omega-3 DHA-rich ingredient in liquid suspension — in feed for Atlantic salmon, evaluating the ingredient’s effect on the feed production process. Variables examined included: physical pellet quality, expansion parameters and microstructure and later its digestibility. AlgaPrime™ DHA can be incorporated at two different moments in the feed production process: into the mix prior to extrusion and during pellet coating. Therefore, the maximum levels of AlgaPrime™ DHA inclusion in both moments was studied. An array of diets was produced and tested, from a control feed using fish meal and soy protein concentrate to feeds with the high inclusion levels of AlgaPrime™ DHA LS. Applying a method that enables numerous comparisons, researchers determined that inclusion of 100 g/kg AlgaPrime™ DHA LS in the mixture was commercially interesting, considering the levels of lipids mostly used in the feed mix. Based on the industry standard practices, researchers tested AlgaPrime™ DHA LS in the pellet coating process and were able to add up to 14% inclusion in a final feed with 36% lipids, which is far above the relevant industrial application levels of omega-3. In a uncommon study design that combines the technical application and nutrition science and after the feed production trials, the research group then looked at four diets containing AlgaPrime™ DHA in the mix, the coating, and a combination of the two, using AlgaPrime™ DHA LS at 10% and 20% inclusions. All four diets showed high nutrient digestibility in Atlantic salmon. For reference, with the inclusion of 8% of AlgaPrime™ DHA LS is possible to replace a 10% inclusion of fish oil in diets with the same omega-3 levels. These findings represent an important step for fish nutrition, illustrating the viability of sustainability gains by increasing the use of ingredients with high concentrations of omega-3, something a reliance on fish oil alone could not accomplish. At the same time, it is great news to the aquaculture industry, enabling the strategic management of omega-3 levels in feed to facilitate the production growth, a much-needed tool in view of increasing pressure on oceans and the supply gap of traditional marine resources. AlgaPrime™ DHA LS is made from a single-cell algae strain grown at scale using industrial fermentation to produce DHA while ensuring feasibility for feed manufacturers and salmon producers. With a higher DHA concentration compared to fish oil and other alternatives, inclusion of AlgaPrime™ DHA LS in feed can maintain or raise omega-3 levels in healthy diets, reducing the dependency for fish oil, thereby helping to preserve the environment.Declared Dividend • Mar 04Dividend of €0.61 announcedShareholders will receive a dividend of €0.61. Ex-date: 19th May 2024 Payment date: 30th May 2024 Dividend yield will be 3.1%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by earnings (50% earnings payout ratio) but not covered by cash flows (206% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 37% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Mar 03Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: EPS: €1.23 (down from €1.53 in FY 2022). Revenue: €1.44b (down 1.0% from FY 2022). Net income: €72.9m (down 19% from FY 2022). Profit margin: 5.0% (down from 6.2% in FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 6.1%. Revenue is forecast to grow 1.3% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.Major Estimate Revision • Feb 06Consensus EPS estimates increase by 18%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate increased from €1.00 to €1.18. Revenue forecast steady at €1.44b. Net income forecast to grow 3.3% next year vs 12% growth forecast for Chemicals industry in the Netherlands. Consensus price target of €22.75 unchanged from last update. Share price fell 3.1% to €18.33 over the past week.Price Target Changed • Feb 06Price target decreased by 9.5% to €22.10Down from €24.42, the current price target is an average from 6 analysts. New target price is 21% above last closing price of €18.33. Stock is down 49% over the past year. The company is forecast to post earnings per share of €1.15 for next year compared to €1.53 last year.Valuation Update With 7 Day Price Move • Jan 27Investor sentiment improves as stock rises 22%After last week's 22% share price gain to €19.58, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 16x in the Chemicals industry in Europe. Total loss to shareholders of 57% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €10.51 per share.분석 기사 • Jan 20Investor Optimism Abounds Corbion N.V. (AMS:CRBN) But Growth Is LackingThere wouldn't be many who think Corbion N.V.'s ( AMS:CRBN ) price-to-earnings (or "P/E") ratio of 14.3x is worth a...분석 기사 • Dec 18Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?Corbion N.V. ( AMS:CRBN ), might not be a large cap stock, but it saw a decent share price growth in the teens level on...공시 • Nov 21+ 2 more updatesCorbion N.V. to Report Fiscal Year 2023 Results on Mar 01, 2024Corbion N.V. announced that they will report fiscal year 2023 results on Mar 01, 2024분석 기사 • Nov 04Estimating The Fair Value Of Corbion N.V. (AMS:CRBN)Key Insights Using the 2 Stage Free Cash Flow to Equity, Corbion fair value estimate is €15.91 Corbion's €17.30 share...Price Target Changed • Oct 25Price target decreased by 9.7% to €26.33Down from €29.17, the current price target is an average from 6 analysts. New target price is 65% above last closing price of €15.94. Stock is down 41% over the past year. The company is forecast to post earnings per share of €0.99 for next year compared to €1.53 last year.Major Estimate Revision • Oct 24Consensus EPS estimates fall by 10%, revenue upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from €1.47b to €1.49b. EPS estimate fell from €1.10 to €0.987 per share. Net income forecast to grow 15% next year vs 2.3% growth forecast for Chemicals industry in the Netherlands. Consensus price target down from €29.17 to €27.50. Share price fell 5.4% to €16.09 over the past week.분석 기사 • Sep 13Corbion (AMS:CRBN) Has A Somewhat Strained Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Reported Earnings • Aug 11First half 2023 earnings released: EPS: €0.48 (vs €0.88 in 1H 2022)First half 2023 results: EPS: €0.48 (down from €0.88 in 1H 2022). Revenue: €738.0m (up 7.4% from 1H 2022). Net income: €28.1m (down 46% from 1H 2022). Profit margin: 3.8% (down from 7.5% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Chemicals industry in the Netherlands. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.분석 기사 • Aug 04Returns On Capital Signal Tricky Times Ahead For Corbion (AMS:CRBN)If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...분석 기사 • Jul 14When Should You Buy Corbion N.V. (AMS:CRBN)?While Corbion N.V. ( AMS:CRBN ) might not be the most widely known stock at the moment, it received a lot of attention...Major Estimate Revision • Jun 27Consensus EPS estimates fall by 26%, revenue upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from €1.41b to €1.49b. EPS estimate fell from €1.54 to €1.14 per share. Net income forecast to shrink 11% next year vs 20% growth forecast for Chemicals industry in the Netherlands . Consensus price target down from €35.40 to €31.63. Share price fell 16% to €21.06 over the past week.Price Target Changed • Jun 26Price target decreased by 14% to €31.63Down from €36.65, the current price target is an average from 4 analysts. New target price is 47% above last closing price of €21.54. Stock is down 28% over the past year. The company is forecast to post earnings per share of €1.14 for next year compared to €1.53 last year.New Risk • Jun 09New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 2.2% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (5.7% operating cash flow to total debt). High level of non-cash earnings (26% accrual ratio). Minor Risk Paying a dividend despite having no free cash flows.분석 기사 • Jun 04Corbion N.V. (AMS:CRBN) Shares Could Be 22% Above Their Intrinsic Value EstimateKey Insights The projected fair value for Corbion is €21.22 based on 2 Stage Free Cash Flow to Equity Current share...공시 • May 18Corbion N.V. Approves Dividend for the Year 2022, Payable on 30 May 2023Corbion N.V. announced that General Shareholders Meeting held on 17 May 2023 approved dividend of €0.56 per ordinary share for the financial year 2022 was also approved. Dividends will be all-cash and will in principle be subject to Dutch dividend withholding tax of 15%. The ex-dividend date is 19 May 2023, the record date is 22 May 2023, and the payment day is 30 May 2023.Upcoming Dividend • May 12Upcoming dividend of €0.56 per share at 1.9% yieldEligible shareholders must have bought the stock before 19 May 2023. Payment date: 30 May 2023. Payout ratio is a comfortable 37% but the company is not cash flow positive. Trailing yield: 1.9%. Lower than top quartile of Dutch dividend payers (6.9%). Lower than average of industry peers (4.9%).Recent Insider Transactions • May 08Insider recently bought €142k worth of stockOn the 3rd of May, O.Y.A.R Rigaud bought around 5k shares on-market at roughly €28.37 per share. This transaction amounted to 5.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €259k more in shares than they have sold in the last 12 months.분석 기사 • Apr 21Here's Why Corbion (AMS:CRBN) Has A Meaningful Debt BurdenSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Major Estimate Revision • Mar 10Consensus EPS estimates fall by 16%, revenue upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from €1.42b to €1.51b. EPS estimate fell from €1.78 to €1.49 per share. Net income forecast to shrink 2.2% next year vs 1.1% decline forecast for Chemicals industry in the Netherlands. Consensus price target down from €38.28 to €36.65. Share price fell 2.4% to €31.14 over the past week.분석 기사 • Mar 10Corbion (AMS:CRBN) Is Paying Out A Dividend Of €0.56Corbion N.V. ( AMS:CRBN ) has announced that it will pay a dividend of €0.56 per share on the 30th of May. The dividend...Reported Earnings • Mar 04Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: EPS: €1.53 (up from €1.33 in FY 2021). Revenue: €1.46b (up 36% from FY 2021). Net income: €90.0m (up 15% from FY 2021). Profit margin: 6.2% (down from 7.3% in FY 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 9.7%. Earnings per share (EPS) missed analyst estimates by 7.4%. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 2.3% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.분석 기사 • Feb 22Is Now An Opportune Moment To Examine Corbion N.V. (AMS:CRBN)?Corbion N.V. ( AMS:CRBN ), is not the largest company out there, but it received a lot of attention from a substantial...분석 기사 • Jan 26Corbion's (AMS:CRBN) Returns On Capital Not Reflecting Well On The BusinessIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...Price Target Changed • Jan 12Price target increased to €36.28Up from €33.03, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of €35.18. Stock is down 11% over the past year. The company is forecast to post earnings per share of €1.64 for next year compared to €1.33 last year.분석 기사 • Dec 20Is Corbion (AMS:CRBN) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...공시 • Dec 13+ 1 more updateCorbion N.V. to Report Fiscal Year 2022 Results on Mar 03, 2023Corbion N.V. announced that they will report fiscal year 2022 results on Mar 03, 2023분석 기사 • Nov 24Calculating The Intrinsic Value Of Corbion N.V. (AMS:CRBN)Today we will run through one way of estimating the intrinsic value of Corbion N.V. ( AMS:CRBN ) by taking the expected...Price Target Changed • Nov 23Price target decreased to €33.03Down from €36.42, the current price target is an average from 5 analysts. New target price is 12% above last closing price of €29.54. Stock is down 29% over the past year. The company is forecast to post earnings per share of €1.60 for next year compared to €1.33 last year.분석 기사 • Nov 09Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?Corbion N.V. ( AMS:CRBN ), might not be a large cap stock, but it saw a decent share price growth in the teens level on...분석 기사 • Oct 08Corbion (AMS:CRBN) Might Be Having Difficulty Using Its Capital EffectivelyFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...이익 및 매출 성장 예측ENXTAM:CRBN - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20281,36310784180512/31/20271,3239383173612/31/20261,2778280164612/31/20251,2677593161N/A9/30/20251,2827096165N/A6/30/20251,29766100169N/A3/31/20251,29256100176N/A12/31/20241,28846100184N/A9/30/20241,2744883177N/A6/30/20241,2605066171N/A3/31/20241,2624741168N/A12/31/20231,2644316165N/A9/30/20231,33848-61121N/A6/30/20231,41254-13977N/A3/31/20231,43572-16858N/A12/31/20221,45890-19739N/A9/30/20221,35076-19032N/A6/30/20221,24363-18425N/A3/31/20221,15770-15524N/A12/31/20211,07178-12622N/A9/30/20211,04097-6559N/A6/30/20211,010116-497N/A3/31/2021998958103N/A12/31/20209877320109N/A9/30/20209924920108N/A6/30/20209972419107N/A3/31/20209872529111N/A12/31/20199762638114N/A9/30/201995337N/A109N/A6/30/201993048N/A105N/A3/31/201991451N/A102N/A12/31/201889754N/A100N/A9/30/201888361N/A109N/A6/30/201886969N/A119N/A3/31/201888077N/A118N/A12/31/201789285N/A118N/A9/30/201790587N/A109N/A6/30/201791889N/A101N/A3/31/201791495N/A112N/A12/31/2016911102N/A123N/A9/30/2016917103N/A124N/A6/30/2016922104N/A126N/A3/31/201692091N/A118N/A12/31/201591878N/A110N/A9/30/201588545N/A93N/A6/30/201585113N/A75N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: CRBN 의 연간 예상 수익 증가율(12.2%)이 saving rate(2.1%)보다 높습니다.수익 vs 시장: CRBN 의 연간 수익(12.2%)이 Dutch 시장(13.8%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: CRBN 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: CRBN 의 수익(연간 2.5%)이 Dutch 시장(연간 9.6%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: CRBN 의 수익(연간 2.5%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: CRBN의 자본 수익률은 3년 후 12.7%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YMaterials 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/20 01:17종가2026/05/20 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Corbion N.V.는 13명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Setu ShardaBarclaysSebastian BrayBerenbergFintan RyanBerenberg10명의 분석가 더 보기
공시 • Apr 24Corbion N.V. Affirms Earnings Guidance for Fiscal Year 2026Corbion N.V. affirmed earnings guidance for Fiscal Year 2026. For the period, the company expects to deliver guidance on all forecasted metrics, including sales growth.
Price Target Changed • Jan 17Price target increased by 8.3% to €24.37Up from €22.50, the current price target is an average from 7 analysts. New target price is 25% above last closing price of €19.42. Stock is down 16% over the past year. The company is forecast to post earnings per share of €1.30 for next year compared to €0.79 last year.
Price Target Changed • Apr 23Price target decreased by 7.0% to €24.33Down from €26.17, the current price target is an average from 6 analysts. New target price is 34% above last closing price of €18.22. Stock is down 3.6% over the past year. The company is forecast to post earnings per share of €1.36 for next year compared to €0.79 last year.
Major Estimate Revision • Feb 06Consensus EPS estimates increase by 18%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate increased from €1.00 to €1.18. Revenue forecast steady at €1.44b. Net income forecast to grow 3.3% next year vs 12% growth forecast for Chemicals industry in the Netherlands. Consensus price target of €22.75 unchanged from last update. Share price fell 3.1% to €18.33 over the past week.
Price Target Changed • Feb 06Price target decreased by 9.5% to €22.10Down from €24.42, the current price target is an average from 6 analysts. New target price is 21% above last closing price of €18.33. Stock is down 49% over the past year. The company is forecast to post earnings per share of €1.15 for next year compared to €1.53 last year.
Price Target Changed • Oct 25Price target decreased by 9.7% to €26.33Down from €29.17, the current price target is an average from 6 analysts. New target price is 65% above last closing price of €15.94. Stock is down 41% over the past year. The company is forecast to post earnings per share of €0.99 for next year compared to €1.53 last year.
공시 • May 15Corbion N.V. Approves Special Dividend for the Financial Year 2025, Payable on 22 May 2026Corbion N.V. at the Annual General Shareholders Meeting held on 13 May 2026 approved dividend of €1.00 per share comprising a special dividend of €0.36 per share for the financial year 2025. Dividend will be all-cash and will in principle be subject to Dutch dividend withholding tax of 15%. The ex-dividend date is 15 May 2026, the record date is 18 May 2026, and the payment date is 22 May 2026.
공시 • May 14+ 1 more updateCorbion N.V. Approves Regular Dividend for the Financial Year 2025, Payable on 22 May 2026Corbion N.V. at the Annual General Shareholders Meeting held on 13 May 2026 approved dividend of €1.00 per share comprising a regular dividend of €0.64 per share for the financial year 2025. Dividend will be all-cash and will in principle be subject to Dutch dividend withholding tax of 15%. The ex-dividend date is 15 May 2026, the record date is 18 May 2026, and the payment date is 22 May 2026.
내러티브 업데이트 • May 09CRBN: Special Dividend And Higher Future P E Could Support Re RatingAnalysts have reduced their fair value estimate for Corbion from €30.00 to €28.00, citing updated assumptions for revenue growth, profit margins and future P/E following recent research, including the Barclays downgrade. Analyst Commentary Recent research has led to a lower fair value estimate for Corbion, but bullish analysts still highlight several supports for the stock, focusing on how current assumptions around revenue, margins and P/E could play out over time.
Upcoming Dividend • May 08Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 15 May 2026. Payment date: 22 May 2026. Payout ratio is a comfortable 50% and this is well supported by cash flows. Trailing yield: 3.4%. Lower than top quartile of Dutch dividend payers (5.0%). Lower than average of industry peers (8.8%).
공시 • Apr 24Corbion N.V. Affirms Earnings Guidance for Fiscal Year 2026Corbion N.V. affirmed earnings guidance for Fiscal Year 2026. For the period, the company expects to deliver guidance on all forecasted metrics, including sales growth.
내러티브 업데이트 • Apr 22CRBN: Special Dividend And Execution On Margins Will Support Upside PotentialThe updated analyst price target for Corbion has shifted slightly to about €24.03 from €24.17, as analysts adjust their assumptions around discount rate, revenue growth, profit margin and future P/E in light of recent research, including the Barclays downgrade. Analyst Commentary Bullish Takeaways Bullish analysts see the updated price target around €24.03 as still leaving some room for upside if Corbion executes well on its revenue and margin assumptions embedded in the models.
내러티브 업데이트 • Apr 08CRBN: Raised Fair Value And Barclays Downgrade Will Shape Risk BalanceAnalysts now set Corbion's fair value at €19.60, up from €18.60. This reflects updated assumptions on growth, margins and P/E multiples, even as some recent research, including a downgrade at Barclays, highlights ongoing risks.
Declared Dividend • Apr 04Dividend of €1.00 announcedShareholders will receive a dividend of €1.00. Ex-date: 15th May 2026 Payment date: 22nd May 2026 Dividend yield will be 5.3%, which is higher than the industry average of 3.2%. Sustainability & Growth Dividend is well covered by both earnings (50% earnings payout ratio) and cash flows (40% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 33% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
내러티브 업데이트 • Mar 24CRBN: Higher Margins And Special Dividend Will Support Future Re RatingAnalysts have maintained their price target for Corbion at €30.00, citing updated assumptions around the discount rate, revenue growth, profit margin and future P/E as the main factors supporting the unchanged view. What's in the News Corbion N.V. proposed a special dividend of €0.36 per share, planned for distribution in 2025.
내러티브 업데이트 • Mar 10CRBN: Special Dividend And Stronger Margins Will Support A More Optimistic OutlookAnalysts have trimmed their price target on Corbion from €24.60 to about €24.17, reflecting updated views on its projected revenue growth, profit margins, and future P/E assumptions. What's in the News Corbion N.V. proposed a special dividend of €0.36 per share for 2025, which may influence your expected cash returns from holding the stock (Key Developments).
Reported Earnings • Mar 02Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: €1.29 (up from €0.79 in FY 2024). Revenue: €1.27b (down 1.6% from FY 2024). Net income: €74.8m (up 63% from FY 2024). Profit margin: 5.9% (up from 3.6% in FY 2024). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.1%. Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
공시 • Feb 27Corbion N.V., Annual General Meeting, May 13, 2026Corbion N.V., Annual General Meeting, May 13, 2026.
공시 • Feb 26+ 1 more updateCorbion N.V. Proposes Dividend for the Year 2025Corbion N.V. proposed to distribute regular dividend of €0.64 per share for 2025.
내러티브 업데이트 • Feb 24CRBN: Higher Future P/E Assumptions Will Support A More Optimistic OutlookAnalysts have raised their price target on Corbion from about €22.73 to €24.60, citing updated assumptions on discount rates, revenue growth, profit margins, and future P/E levels. Valuation Changes Fair Value: Updated estimate increased from about €22.73 to €24.60 per share.
내러티브 업데이트 • Feb 09CRBN: Buyback And Higher Discount Rate Will Pressure Overvalued SharesAnalysts have kept their price target on Corbion steady at €18.60, citing only small adjustments to assumptions around the discount rate, revenue trends, profit margins and future P/E as the basis for this unchanged view. What's in the News Corbion completed a share buyback program, repurchasing 577,615 shares for €10 million, equal to 0.99% of the company.
내러티브 업데이트 • Jan 26CRBN: Higher Future P/E And Execution Risks Will Shape EUR 18 OutlookNarrative Update on Corbion Analysts have raised their fair value estimate for Corbion to €18.60 from €18.00. This reflects updated views on discount rates, long term revenue trends, profit margins, and a higher future P/E assumption, alongside recent Street research where a key price target moved to €18 from €16.50.
Price Target Changed • Jan 17Price target increased by 8.3% to €24.37Up from €22.50, the current price target is an average from 7 analysts. New target price is 25% above last closing price of €19.42. Stock is down 16% over the past year. The company is forecast to post earnings per share of €1.30 for next year compared to €0.79 last year.
분석 기사 • Jan 14Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?Corbion N.V. ( AMS:CRBN ), is not the largest company out there, but it saw a double-digit share price rise of over 10...
내러티브 업데이트 • Jan 11CRBN: Future P/E Reset And Margin Assumptions Will Shape EUR 18 OutlookAnalysts have raised their price target for Corbion to €18 from €16.50, citing updated assumptions on revenue trends, margins and future P/E as the main factors behind the change. Analyst Commentary The revised €18 price target still comes with a Hold stance, which signals a measured view on Corbion.
내러티브 업데이트 • Dec 26CRBN: Higher EUR 18 Outlook Will Test Margin Delivery Amid Muted DemandAnalysts have raised their fair value estimate for Corbion to EUR 18 from EUR 14, reflecting increased confidence in the company’s profit margin outlook and a willingness to apply a higher future earnings multiple despite more muted revenue growth expectations. Analyst Commentary Bearish analysts acknowledge the higher fair value estimate but continue to highlight a cautious stance on Corbion’s near term prospects, emphasizing that the improved target largely reflects valuation mechanics rather than a fundamental re-rating of the growth outlook.
내러티브 업데이트 • Dec 12CRBN: Margin Improvements And Buybacks Will Support A Future Re-RatingAnalysts have lowered their fair value price target on Corbion to EUR 30.00 from EUR 31.90, citing tempered expectations for long term revenue growth and profit margins, even as some recent Street research has modestly raised nearer term share price targets. Analyst Commentary Bullish analysts highlight that the recent upward revision in near term price targets, even from a relatively low base, reflects growing confidence that Corbion can stabilize its earnings profile and execute on margin improvement initiatives.
분석 기사 • Nov 14Corbion N.V. (AMS:CRBN) Shares Could Be 35% Below Their Intrinsic Value EstimateKey Insights Using the 2 Stage Free Cash Flow to Equity, Corbion fair value estimate is €28.50 Current share price of...
공시 • Oct 09+ 2 more updatesCorbion N.V. to Report Fiscal Year 2025 Results on Feb 26, 2026Corbion N.V. announced that they will report fiscal year 2025 results on Feb 26, 2026
Reported Earnings • Aug 05First half 2025 earnings released: EPS: €0.73 (vs €0.39 in 1H 2024)First half 2025 results: EPS: €0.73 (up from €0.39 in 1H 2024). Revenue: €645.6m (up 1.3% from 1H 2024). Net income: €42.4m (up 87% from 1H 2024). Profit margin: 6.6% (up from 3.6% in 1H 2024). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.
분석 기사 • Jun 23Corbion N.V.'s (AMS:CRBN) Intrinsic Value Is Potentially 65% Above Its Share PriceKey Insights The projected fair value for Corbion is €30.72 based on 2 Stage Free Cash Flow to Equity Current share...
Upcoming Dividend • May 09Upcoming dividend of €0.64 per shareEligible shareholders must have bought the stock before 16 May 2025. Payment date: 27 May 2025. Payout ratio is on the higher end at 81%, however this is supported by cash flows. Trailing yield: 3.3%. Lower than top quartile of Dutch dividend payers (5.6%). Higher than average of industry peers (2.9%).
분석 기사 • May 07Here's Why Shareholders Should Examine Corbion N.V.'s (AMS:CRBN) CEO Compensation Package More CloselyKey Insights Corbion's Annual General Meeting to take place on 14th of May Salary of €725.0k is part of CEO Olivier...
Price Target Changed • Apr 23Price target decreased by 7.0% to €24.33Down from €26.17, the current price target is an average from 6 analysts. New target price is 34% above last closing price of €18.22. Stock is down 3.6% over the past year. The company is forecast to post earnings per share of €1.36 for next year compared to €0.79 last year.
분석 기사 • Apr 10At €17.39, Is Corbion N.V. (AMS:CRBN) Worth Looking At Closely?Corbion N.V. ( AMS:CRBN ), might not be a large cap stock, but it saw significant share price movement during recent...
Declared Dividend • Apr 04Final dividend of €0.64 announcedShareholders will receive a dividend of €0.64. Ex-date: 16th May 2025 Payment date: 27th May 2025 Dividend yield will be 3.4%, which is higher than the industry average of 3.2%. Sustainability & Growth Dividend is covered by both earnings (81% earnings payout ratio) and cash flows (37% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 108% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
공시 • Apr 03Corbion N.V. announces Annual dividend, payable on May 27, 2025Corbion N.V. announced Annual dividend of EUR 0.6400 per share payable on May 27, 2025, ex-date on May 16, 2025 and record date on May 19, 2025.
분석 기사 • Mar 26Corbion's (AMS:CRBN) Earnings May Just Be The Starting PointCorbion N.V.'s ( AMS:CRBN ) earnings announcement last week was disappointing for investors, despite the decent profit...
새로운 내러티브 • Mar 02Expanding Into Natural Antioxidants And Efficiency Improvements Will Drive Future Success Strategic initiatives and operational optimizations are expected to significantly enhance EBITDA margins and net margins.
Reported Earnings • Feb 28Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: EPS: €0.79 (down from €1.23 in FY 2023). Revenue: €1.29b (down 11% from FY 2023). Net income: €45.9m (down 37% from FY 2023). Profit margin: 3.6% (down from 5.0% in FY 2023). The decrease in margin was driven by lower revenue. Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates significantly. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings.
분석 기사 • Feb 28Here's What To Make Of Corbion's (AMS:CRBN) Decelerating Rates Of ReturnWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...
공시 • Feb 28Corbion N.V., Annual General Meeting, May 14, 2025Corbion N.V., Annual General Meeting, May 14, 2025.
공시 • Feb 27Corbion N.V. Proposes Regular Cash DividendCorbion N.V. proposed a regular cash dividend increase of +5% to €0.64 per ordinary share to be submitted for approval to the annual General Meeting of Shareholders.
Buy Or Sell Opportunity • Feb 14Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 4.4% to €22.80. The fair value is estimated to be €18.99, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has declined by 12%. For the next 3 years, revenue is forecast to grow by 1.5% per annum. Earnings are also forecast to grow by 10% per annum over the same time period.
분석 기사 • Dec 18Risks To Shareholder Returns Are Elevated At These Prices For Corbion N.V. (AMS:CRBN)It's not a stretch to say that Corbion N.V.'s ( AMS:CRBN ) price-to-earnings (or "P/E") ratio of 15.8x right now seems...
분석 기사 • Nov 18Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?Corbion N.V. ( AMS:CRBN ), might not be a large cap stock, but it received a lot of attention from a substantial price...
분석 기사 • Oct 31An Intrinsic Calculation For Corbion N.V. (AMS:CRBN) Suggests It's 26% UndervaluedKey Insights Using the 2 Stage Free Cash Flow to Equity, Corbion fair value estimate is €31.60 Corbion's €23.28 share...
Buy Or Sell Opportunity • Oct 30Now 21% undervaluedOver the last 90 days, the stock has risen 24% to €25.42. The fair value is estimated to be €32.03, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has declined by 12%. Revenue is forecast to decline by 5.2% in 2 years. Earnings are forecast to grow by 15% in the next 2 years.
New Risk • Oct 30New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.5% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.5% per year for the foreseeable future. Minor Risks High level of debt (51% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
공시 • Oct 25+ 1 more updateCorbion N.V. to Report Q2, 2025 Results on Jul 31, 2025Corbion N.V. announced that they will report Q2, 2025 results on Jul 31, 2025
분석 기사 • Sep 26Corbion (AMS:CRBN) Takes On Some Risk With Its Use Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Aug 12First half 2024 earnings released: EPS: €0.39 (vs €0.26 in 1H 2023)First half 2024 results: EPS: €0.39 (up from €0.26 in 1H 2023). Revenue: €637.1m (flat on 1H 2023). Net income: €22.7m (up 47% from 1H 2023). Profit margin: 3.6% (up from 2.4% in 1H 2023). Revenue is forecast to stay flat during the next 3 years compared to a 4.7% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.
분석 기사 • Jul 18The Price Is Right For Corbion N.V. (AMS:CRBN)It's not a stretch to say that Corbion N.V.'s ( AMS:CRBN ) price-to-earnings (or "P/E") ratio of 16.1x right now seems...
분석 기사 • Jun 20Corbion N.V. (AMS:CRBN) Shares Could Be 25% Below Their Intrinsic Value EstimateKey Insights Using the 2 Stage Free Cash Flow to Equity, Corbion fair value estimate is €25.18 Corbion is estimated to...
Buy Or Sell Opportunity • May 31Now 20% undervaluedOver the last 90 days, the stock has risen 4.2% to €20.38. The fair value is estimated to be €25.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has declined by 9.7%. For the next 3 years, revenue is forecast to grow by 0.3% per annum. Earnings are also forecast to grow by 17% per annum over the same time period.
분석 기사 • May 08Here's Why Shareholders Should Examine Corbion N.V.'s (AMS:CRBN) CEO Compensation Package More CloselyKey Insights Corbion will host its Annual General Meeting on 15th of May Salary of €713.0k is part of CEO Olivier...
Declared Dividend • May 03Final dividend of €0.61 announcedShareholders will receive a dividend of €0.61. Ex-date: 17th May 2024 Payment date: 28th May 2024 Dividend yield will be 3.4%, which is higher than the industry average of 3.2%. Sustainability & Growth Dividend is covered by earnings (49% earnings payout ratio) but not covered by cash flows (224% cash payout ratio). The dividend has increased by an average of 15% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 54% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Buy Or Sell Opportunity • Apr 26Now 23% overvaluedOver the last 90 days, the stock has fallen 1.5% to €19.28. The fair value is estimated to be €15.63, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has declined by 9.7%. For the next 3 years, revenue is forecast to grow by 0.6% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.
분석 기사 • Apr 17Does Corbion (AMS:CRBN) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
공시 • Apr 12Corbion Appoints Masha Vis-Mertens as Chief Human Resources Officer and Member of the Executive Committee as of 1 May 2024Corbion announced appointment of Masha Vis-Mertens as Chief Human Resources Officer and member of the Executive Committee as of 1 May 2024. Masha Vis-Mertens, a Dutch national, joins Corbion from Switzerland where she was most recently Chief Human Resources Officer of Barry Callebaut, a global Cocoa and Chocolate Manufacturer. Over her career, she has lived in various regions and countries and has been a successful leader in HR, Commercial and Supply Chain roles. In her previous positions she gained a wealth of experience in talent development, diversity and inclusion, culture, and organizational transformation that she will be bringing to Corbion. Masha brings a diverse and multi-cultural background and a fresh perspective. She worked internationally throughout her career and is fluent in Dutch, German, French and English.
공시 • Apr 03Kingswood Capital Management, L.P. completed the acquisition of Emulsifiers business from Corbion N.V.Kingswood Capital Management, L.P. singed a binding agreement to acquire Emulsifiers business from Corbion N.V for $362 million on January 26, 2024. The purchase price paid for the business is $362 million with expected net cash proceeds of approximately $275 million, post tax and transaction costs. The sale, which is contingent upon the satisfaction of certain conditions, including regulatory approvals and transaction is expected to close in the second quarter of this year. Kirkland & Ellis LLP acted as legal advisor and Configure Partners, LLC acted as debt advisor to Kingswood Capital Management, L.P. Lazard B.V. acted as financial advisor and Stinson LLP acted as legal advisor to Corbion N.V. Kingswood Capital Management, L.P. completed the acquisition of Emulsifiers business from Corbion N.V on April 2, 2024. The emulsifiers business, moving forward, will operate under the name PATCO Products, LLC and Vice President of Emulsifiers at Corbion, John Miller, will continue to lead the Company as its Chief Executive Officer.
공시 • Mar 05Corbion Announces Preliminary Results of New Study from Millennial Salmon ProjectCorbion announced preliminary results of a new study from the Millennial Salmon Project, a strategic partnership among organizations along the value chain of salmon production. Conducted by Nofima and recently published in Aquaculture, the study confirms that AlgaPrime™ DHA can be added at varying levels without negatively impacting feed quality, and actually promoting a more stable process and pellet quality. Primarily funded by the Research Council of Norway and made up of leading organizations Nofima, InnovaFeed, Corbion,Cargill, MOWI, Labeyrie Fine Foods, SINTEF Ocean and Auchan, the Millennial Salmon Project aims to create the world’s most sustainable farmed salmon using novel ingredients with a low carbon footprint and a focus on the circular economy. The first round of research sought to determine optimal inclusion levels of AlgaPrime™ DHA LS — Corbion’s algae-based omega-3 DHA-rich ingredient in liquid suspension — in feed for Atlantic salmon, evaluating the ingredient’s effect on the feed production process. Variables examined included: physical pellet quality, expansion parameters and microstructure and later its digestibility. AlgaPrime™ DHA can be incorporated at two different moments in the feed production process: into the mix prior to extrusion and during pellet coating. Therefore, the maximum levels of AlgaPrime™ DHA inclusion in both moments was studied. An array of diets was produced and tested, from a control feed using fish meal and soy protein concentrate to feeds with the high inclusion levels of AlgaPrime™ DHA LS. Applying a method that enables numerous comparisons, researchers determined that inclusion of 100 g/kg AlgaPrime™ DHA LS in the mixture was commercially interesting, considering the levels of lipids mostly used in the feed mix. Based on the industry standard practices, researchers tested AlgaPrime™ DHA LS in the pellet coating process and were able to add up to 14% inclusion in a final feed with 36% lipids, which is far above the relevant industrial application levels of omega-3. In a uncommon study design that combines the technical application and nutrition science and after the feed production trials, the research group then looked at four diets containing AlgaPrime™ DHA in the mix, the coating, and a combination of the two, using AlgaPrime™ DHA LS at 10% and 20% inclusions. All four diets showed high nutrient digestibility in Atlantic salmon. For reference, with the inclusion of 8% of AlgaPrime™ DHA LS is possible to replace a 10% inclusion of fish oil in diets with the same omega-3 levels. These findings represent an important step for fish nutrition, illustrating the viability of sustainability gains by increasing the use of ingredients with high concentrations of omega-3, something a reliance on fish oil alone could not accomplish. At the same time, it is great news to the aquaculture industry, enabling the strategic management of omega-3 levels in feed to facilitate the production growth, a much-needed tool in view of increasing pressure on oceans and the supply gap of traditional marine resources. AlgaPrime™ DHA LS is made from a single-cell algae strain grown at scale using industrial fermentation to produce DHA while ensuring feasibility for feed manufacturers and salmon producers. With a higher DHA concentration compared to fish oil and other alternatives, inclusion of AlgaPrime™ DHA LS in feed can maintain or raise omega-3 levels in healthy diets, reducing the dependency for fish oil, thereby helping to preserve the environment.
Declared Dividend • Mar 04Dividend of €0.61 announcedShareholders will receive a dividend of €0.61. Ex-date: 19th May 2024 Payment date: 30th May 2024 Dividend yield will be 3.1%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by earnings (50% earnings payout ratio) but not covered by cash flows (206% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 37% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Mar 03Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: EPS: €1.23 (down from €1.53 in FY 2022). Revenue: €1.44b (down 1.0% from FY 2022). Net income: €72.9m (down 19% from FY 2022). Profit margin: 5.0% (down from 6.2% in FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 6.1%. Revenue is forecast to grow 1.3% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.
Major Estimate Revision • Feb 06Consensus EPS estimates increase by 18%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate increased from €1.00 to €1.18. Revenue forecast steady at €1.44b. Net income forecast to grow 3.3% next year vs 12% growth forecast for Chemicals industry in the Netherlands. Consensus price target of €22.75 unchanged from last update. Share price fell 3.1% to €18.33 over the past week.
Price Target Changed • Feb 06Price target decreased by 9.5% to €22.10Down from €24.42, the current price target is an average from 6 analysts. New target price is 21% above last closing price of €18.33. Stock is down 49% over the past year. The company is forecast to post earnings per share of €1.15 for next year compared to €1.53 last year.
Valuation Update With 7 Day Price Move • Jan 27Investor sentiment improves as stock rises 22%After last week's 22% share price gain to €19.58, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 16x in the Chemicals industry in Europe. Total loss to shareholders of 57% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €10.51 per share.
분석 기사 • Jan 20Investor Optimism Abounds Corbion N.V. (AMS:CRBN) But Growth Is LackingThere wouldn't be many who think Corbion N.V.'s ( AMS:CRBN ) price-to-earnings (or "P/E") ratio of 14.3x is worth a...
분석 기사 • Dec 18Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?Corbion N.V. ( AMS:CRBN ), might not be a large cap stock, but it saw a decent share price growth in the teens level on...
공시 • Nov 21+ 2 more updatesCorbion N.V. to Report Fiscal Year 2023 Results on Mar 01, 2024Corbion N.V. announced that they will report fiscal year 2023 results on Mar 01, 2024
분석 기사 • Nov 04Estimating The Fair Value Of Corbion N.V. (AMS:CRBN)Key Insights Using the 2 Stage Free Cash Flow to Equity, Corbion fair value estimate is €15.91 Corbion's €17.30 share...
Price Target Changed • Oct 25Price target decreased by 9.7% to €26.33Down from €29.17, the current price target is an average from 6 analysts. New target price is 65% above last closing price of €15.94. Stock is down 41% over the past year. The company is forecast to post earnings per share of €0.99 for next year compared to €1.53 last year.
Major Estimate Revision • Oct 24Consensus EPS estimates fall by 10%, revenue upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from €1.47b to €1.49b. EPS estimate fell from €1.10 to €0.987 per share. Net income forecast to grow 15% next year vs 2.3% growth forecast for Chemicals industry in the Netherlands. Consensus price target down from €29.17 to €27.50. Share price fell 5.4% to €16.09 over the past week.
분석 기사 • Sep 13Corbion (AMS:CRBN) Has A Somewhat Strained Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Reported Earnings • Aug 11First half 2023 earnings released: EPS: €0.48 (vs €0.88 in 1H 2022)First half 2023 results: EPS: €0.48 (down from €0.88 in 1H 2022). Revenue: €738.0m (up 7.4% from 1H 2022). Net income: €28.1m (down 46% from 1H 2022). Profit margin: 3.8% (down from 7.5% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Chemicals industry in the Netherlands. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
분석 기사 • Aug 04Returns On Capital Signal Tricky Times Ahead For Corbion (AMS:CRBN)If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...
분석 기사 • Jul 14When Should You Buy Corbion N.V. (AMS:CRBN)?While Corbion N.V. ( AMS:CRBN ) might not be the most widely known stock at the moment, it received a lot of attention...
Major Estimate Revision • Jun 27Consensus EPS estimates fall by 26%, revenue upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from €1.41b to €1.49b. EPS estimate fell from €1.54 to €1.14 per share. Net income forecast to shrink 11% next year vs 20% growth forecast for Chemicals industry in the Netherlands . Consensus price target down from €35.40 to €31.63. Share price fell 16% to €21.06 over the past week.
Price Target Changed • Jun 26Price target decreased by 14% to €31.63Down from €36.65, the current price target is an average from 4 analysts. New target price is 47% above last closing price of €21.54. Stock is down 28% over the past year. The company is forecast to post earnings per share of €1.14 for next year compared to €1.53 last year.
New Risk • Jun 09New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 2.2% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (5.7% operating cash flow to total debt). High level of non-cash earnings (26% accrual ratio). Minor Risk Paying a dividend despite having no free cash flows.
분석 기사 • Jun 04Corbion N.V. (AMS:CRBN) Shares Could Be 22% Above Their Intrinsic Value EstimateKey Insights The projected fair value for Corbion is €21.22 based on 2 Stage Free Cash Flow to Equity Current share...
공시 • May 18Corbion N.V. Approves Dividend for the Year 2022, Payable on 30 May 2023Corbion N.V. announced that General Shareholders Meeting held on 17 May 2023 approved dividend of €0.56 per ordinary share for the financial year 2022 was also approved. Dividends will be all-cash and will in principle be subject to Dutch dividend withholding tax of 15%. The ex-dividend date is 19 May 2023, the record date is 22 May 2023, and the payment day is 30 May 2023.
Upcoming Dividend • May 12Upcoming dividend of €0.56 per share at 1.9% yieldEligible shareholders must have bought the stock before 19 May 2023. Payment date: 30 May 2023. Payout ratio is a comfortable 37% but the company is not cash flow positive. Trailing yield: 1.9%. Lower than top quartile of Dutch dividend payers (6.9%). Lower than average of industry peers (4.9%).
Recent Insider Transactions • May 08Insider recently bought €142k worth of stockOn the 3rd of May, O.Y.A.R Rigaud bought around 5k shares on-market at roughly €28.37 per share. This transaction amounted to 5.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €259k more in shares than they have sold in the last 12 months.
분석 기사 • Apr 21Here's Why Corbion (AMS:CRBN) Has A Meaningful Debt BurdenSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Major Estimate Revision • Mar 10Consensus EPS estimates fall by 16%, revenue upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from €1.42b to €1.51b. EPS estimate fell from €1.78 to €1.49 per share. Net income forecast to shrink 2.2% next year vs 1.1% decline forecast for Chemicals industry in the Netherlands. Consensus price target down from €38.28 to €36.65. Share price fell 2.4% to €31.14 over the past week.
분석 기사 • Mar 10Corbion (AMS:CRBN) Is Paying Out A Dividend Of €0.56Corbion N.V. ( AMS:CRBN ) has announced that it will pay a dividend of €0.56 per share on the 30th of May. The dividend...
Reported Earnings • Mar 04Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: EPS: €1.53 (up from €1.33 in FY 2021). Revenue: €1.46b (up 36% from FY 2021). Net income: €90.0m (up 15% from FY 2021). Profit margin: 6.2% (down from 7.3% in FY 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 9.7%. Earnings per share (EPS) missed analyst estimates by 7.4%. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 2.3% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
분석 기사 • Feb 22Is Now An Opportune Moment To Examine Corbion N.V. (AMS:CRBN)?Corbion N.V. ( AMS:CRBN ), is not the largest company out there, but it received a lot of attention from a substantial...
분석 기사 • Jan 26Corbion's (AMS:CRBN) Returns On Capital Not Reflecting Well On The BusinessIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...
Price Target Changed • Jan 12Price target increased to €36.28Up from €33.03, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of €35.18. Stock is down 11% over the past year. The company is forecast to post earnings per share of €1.64 for next year compared to €1.33 last year.
분석 기사 • Dec 20Is Corbion (AMS:CRBN) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
공시 • Dec 13+ 1 more updateCorbion N.V. to Report Fiscal Year 2022 Results on Mar 03, 2023Corbion N.V. announced that they will report fiscal year 2022 results on Mar 03, 2023
분석 기사 • Nov 24Calculating The Intrinsic Value Of Corbion N.V. (AMS:CRBN)Today we will run through one way of estimating the intrinsic value of Corbion N.V. ( AMS:CRBN ) by taking the expected...
Price Target Changed • Nov 23Price target decreased to €33.03Down from €36.42, the current price target is an average from 5 analysts. New target price is 12% above last closing price of €29.54. Stock is down 29% over the past year. The company is forecast to post earnings per share of €1.60 for next year compared to €1.33 last year.
분석 기사 • Nov 09Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?Corbion N.V. ( AMS:CRBN ), might not be a large cap stock, but it saw a decent share price growth in the teens level on...
분석 기사 • Oct 08Corbion (AMS:CRBN) Might Be Having Difficulty Using Its Capital EffectivelyFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...